Carbetocin on Myocardial Repolarization Dynamics in Obstetrics Study (CaRDIO)

University of British Columbia

Status and phase: Completed; Phase 4

Conditions: Cardiac Arrythmias

Treatments: Drug: Carbetocin

Study type: Interventional

Funder types: Other

Identifiers

NCT03716076

H18-02232

Details and patient eligibility

About

Relationship between carbetocin dose on transmural dispersion of repolarization (TDR).

Full description

Carbetocin is a uterotonic used to prevent postpartum hemorrhage. Although it has been proven to be completely safe, little is known about its effects on the electrical activity of the heart. The investigators aim to determine its effect on myocardial repolarization dynamics

Enrollment: 50 patients

Sex: Female

Ages: 19+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Pregnant patients ≥ 36 weeks gestation, for elective Cesarean delivery under neuraxial anesthesia
• American Society of Anesthesiologists (ASA) class 2
• Patients ≥ 19 years of age

Exclusion criteria

• Long QT syndrome
• Cardiac disease or rhythm abnormalities
• Family history of long QT syndrome or abnormal cardiac conduction
• Currently taking medication that is known to prolong the QT interval
• Women who are high risk for uterine atony as outlined in SOGC
• Known allergic reaction or hypersensitivity to Carbetocin or any other oxytocin homologue
• Patients who are unable to give informed consent because of a language barrier as the study team only speaks English and will be unable to complete consent process and study procedure appropriately.

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

50 participants in 2 patient groups

Participant receives 50 mcg of carbetocin post-delivery.

Experimental group

Description:

Participant receives 50 mcg of carbetocin post-delivery.

Treatment:

Drug: Carbetocin

Participant receives 100 mcg of carbetocin post-delivery.

Experimental group

Description:

Participant receives 100 mcg of carbetocin post-delivery.

Treatment:

Drug: Carbetocin